⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist.

The sci-fi-sounding idea

That the bacteria in your gut could influence whether a cancer treatment works or not sounds odd. But that’s exactly what the latest evidence reviewed by The American Journal of Medicine suggests: patients who receive encapsulated fecal microbiota from healthy donors before starting checkpoint inhibitor immunotherapy respond better and suffer fewer severe adverse effects.

It’s not magic. It’s the gut-immunity axis, and it’s changing how we understand cancer treatment.

What does the review say?

The article reviews the state of the art in cancer immunotherapy and highlights four fronts that are advancing rapidly:

1. Encapsulated fecal microbiota before checkpoint inhibitors — the most striking finding. In patients who received healthy donor microbiota transplant before immunotherapy, better responses and less severe toxicity were observed. This is not entirely a new idea: in 2021, an anti-PD-1 resistant melanoma trial already showed that fecal microbiota transplantation could restore treatment response in a relevant proportion of patients (Davar et al., Science, PMID 33542131). What’s new is that the strategy is moving towards encapsulated and oral forms, much easier to administer.

2. Next-generation CAR-T and CAR-NK for solid tumors — current CAR-Ts have been a game-changer in hematologic malignancies (leukemias, lymphomas, myeloma), but they hit a wall with solid tumors. New constructs incorporate a second CAR, the ability to produce antibodies against checkpoints or generate IL-12/IL-15, cytokines that recruit and activate more immune cells in the tumor microenvironment.

3. Genetically edited B and plasma cells — clones that produce cytotoxic antibodies against the tumor directly in vivo, rather than manufacturing them outside and administering them.

4. Neoantigen vaccines (peptides or mRNA) combined with checkpoint inhibitors — customizing the vaccine according to each patient’s specific tumor mutations and combining it with immunotherapy to boost the response.

Why it matters to clinicians (and patients)

Immunotherapy is already first-line for many tumors, largely thanks to monoclonal antibodies, antibody-drug conjugates, checkpoint inhibitors, and CAR-Ts. The challenge now is twofold: make them work in solid tumors and predict who will respond.

The microbiota opens a practical door: if an encapsulated microbiota transplant (an oral product, without invasive procedures) can improve response to checkpoint inhibitors, we’re talking about a cheap, reproducible intervention with a manageable safety profile that could be applied before starting treatment. Ongoing trials will tell whether this is confirmed in large randomized studies.

But with caution

• It’s a narrative review: it summarizes the literature, does not provide original trial data.
• Microbiota transplantation is still in the research phase; it’s not standard clinical practice.
• Next-generation CAR-Ts and edited B cells are in early development, with the usual challenges in solid tumors: infiltration, immunosuppressive microenvironment, and toxicity.
• Neoantigen vaccines are promising but complex and expensive to produce on demand.
• As always in immunotherapy: patient selection and toxicity management will remain at the center of clinical practice.

Reflection

Ten years ago, “training the immune system against cancer” was a promise. Today it’s a reality with several generations of drugs, and the frontier has shifted: it’s no longer just which drug, but in what biological context — including our bacteria — we administer it. 2026 immunotherapy smells like true personalized medicine: microbiota, edited cells, and custom vaccines, all around a single principle, making the body itself recognize and eliminate the tumor.

References

Esnaola GR, Goetzl EJ. Advances in Cancer Immunotherapy. The American Journal of Medicine, 2026. DOI: 10.1016/j.amjmed.2026.07.012 · link · PMID: 42498103

Davar D, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science, 2021. DOI: 10.1126/science.abf3363 · link · PMID: 33542131

— This analysis was generated by ANGIE (Always Next to Guide, Inspire and Empower), an artificial intelligence system with SOUL profiles, designed by Dr. Javier Pumares Pérez.

Connect on LinkedIn · ppj.es